Catalyst Pharmaceuticals Revenue 2006-2019 | CPRX

Catalyst Pharmaceuticals revenue from 2006 to 2019. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Catalyst Pharmaceuticals Annual Revenue
(Millions of US $)
2018 $1
2017 $
2016 $
2015 $
2014 $
2013 $
2012 $
2011 $
2010 $0
2009 $
2008 $
2007 $
2006 $
2005 $
Catalyst Pharmaceuticals Quarterly Revenue
(Millions of US $)
Q2 2019 $29
Q1 2019 $12
Q4 2018
Q3 2018
Q2 2018
Q1 2018
Q4 2017
Q3 2017
Q2 2017
Q1 2017
Q4 2016
Q3 2016
Q2 2016
Q1 2016
Q4 2015
Q3 2015
Q2 2015
Q1 2015
Q4 2014
Q3 2014
Q2 2014
Q1 2014
Q4 2013
Q3 2013
Q2 2013
Q1 2013
Q4 2012
Q3 2012
Q2 2012
Q1 2012
Q4 2011
Q3 2011
Q2 2011
Q1 2011
Q4 2010
Q3 2010
Q2 2010
Q1 2010
Q4 2009
Q3 2009
Q2 2009
Q1 2009
Q4 2008
Q3 2008
Q2 2008
Q1 2008
Q4 2007
Q3 2007
Q2 2007
Q1 2007
Q4 2006
Q3 2006
Q2 2006
Q1 2006
Q3 2005
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.497B $0.001B
CATALYST PHARMACEUTICAL PARTNERS, INC. is a biopharmaceutical company focused on the development and commercialization of prescription drugs for the treatment of addiction and obsessive compulsive disorders. The Company has obtained from Brookhaven National Laboratory an exclusive worldwide license for Brookhaven's patent portfolio in the US relating to the right to use vigabatrin to treat a wide variety of substance addictions and obsessive compulsive disorders. Catalyst has also been granted rights to Brookhaven's vigabatrin-related foreign patents or patents pending worldwide. The Company's initial product candidate based on vigabatrin is CPP-109. CPP-109 has been granted `Fast Track` status by the U.S. Food & Drug Administration for the treatment of cocaine addiction. This indicates that the FDA has recognized that CPP-109 is intended for the treatment of a serious or life-threatening condition for which there is no effective treatment and which demonstrates the potential to address unmet medical needs.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $61.352B 37.78
Takeda Pharmaceutical (TAK) Japan $53.895B 8.43
Astellas Pharma (ALPMY) Japan $29.205B 13.91
Merck (MKGAF) Germany $14.895B 20.33
Eisai (ESALY) Japan $14.570B 22.30
Grifols, S.A (GRFS) Spain $13.992B 17.85
UCB SA (UCBJF) Belgium $13.839B 0.00
Ono Pharmaceutical (OPHLF) Japan $9.212B 19.69
Ionis Pharmaceuticals (IONS) United States $8.815B 19.01
Neurocrine Biosciences (NBIX) United States $8.272B 0.00
IPSEN SA ADR (IPSEY) France $7.776B 0.00
Sage Therapeutics (SAGE) United States $7.260B 0.00
Recordati Industria Chimica E Farmaceutica S.P.A (RCDTF) Italy $7.257B 0.00
Catalent (CTLT) United States $7.112B 28.11
Jazz Pharmaceuticals (JAZZ) Ireland $6.719B 8.84
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $6.118B 0.00
STADA ARZNEIMI (STDAF) Germany $5.547B 0.00
Orion OYJ (ORINY) Finland $5.275B 27.16
Hypermarcas (HYPMY) Brazil $5.216B 18.75
United Therapeutics (UTHR) United States $3.591B 0.00
FibroGen (FGEN) United States $3.241B 81.07
Evotec AG (EVTCY) Germany $3.183B 43.58
Arrowhead Pharmaceuticals (ARWR) United States $3.086B 70.76
Nektar Therapeutics (NKTR) United States $2.995B 0.00
Taro Pharmaceutical Industries (TARO) Israel $2.932B 10.51
PTC Therapeutics (PTCT) United States $2.172B 0.00
Tilray (TLRY) Canada $2.047B 0.00
Xencor (XNCR) United States $1.959B 42.71
Portola Pharmaceuticals (PTLA) United States $1.840B 0.00
Zogenix (ZGNX) United States $1.816B 0.00
Corcept Therapeutics (CORT) United States $1.603B 22.03
CLINIGEN GP (CLIGF) United Kingdom $1.577B 0.00
Pacira Pharmaceuticals (PCRX) United States $1.569B 57.11
USANA Health Sciences (USNA) United States $1.522B 15.27
Heron Therapeutics (HRTX) United States $1.428B 0.00
Ironwood Pharmaceuticals (IRWD) United States $1.379B 0.00
Enanta Pharmaceuticals (ENTA) United States $1.162B 19.17
Radius Health (RDUS) United States $1.131B 0.00
ArQule (ARQL) United States $1.032B 0.00
Theravance Biopharma (TBPH) Cayman Islands $1.005B 0.00
TherapeuticsMD (TXMD) United States $0.928B 0.00
Aerie Pharmaceuticals (AERI) United States $0.926B 0.00
Spectrum Pharmaceuticals (SPPI) United States $0.847B 0.00
Endo (ENDP) Ireland $0.839B 1.48
Dova Pharmaceuticals (DOVA) United States $0.818B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $0.814B 3.63
Organogenesis Holdings (ORGO) United States $0.716B 0.00
Concordia (CXRXF) Canada $0.633B 0.00
Karyopharm Therapeutics (KPTI) United States $0.632B 0.00
Akebia Therapeutics (AKBA) United States $0.512B 0.00
Flexion Therapeutics (FLXN) United States $0.509B 0.00
Aptorum Group (APM) Hong Kong, SAR China $0.463B 0.00
Lannett Co Inc (LCI) United States $0.447B 4.71
Siga Technologies (SIGA) United States $0.447B 1.04
ChemoCentryx (CCXI) United States $0.441B 0.00
Indivior (INVVY) United States $0.437B 1.58
Translate Bio (TBIO) United States $0.414B 0.00
Crinetics Pharmaceuticals (CRNX) United States $0.399B 0.00
Collegium Pharmaceutical (COLL) United States $0.395B 0.00
Innate Pharma SA (IPHYF) France $0.392B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $0.387B 0.00
BioSpecifics Technologies Corp (BSTC) United States $0.368B 16.75
Harpoon Therapeutics (HARP) United States $0.340B 0.00
ImmunoGen (IMGN) United States $0.337B 0.00
DURECT (DRRX) United States $0.326B 0.00
Dermira (DERM) United States $0.310B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.301B 0.00
Ardelyx (ARDX) United States $0.292B 0.00
OptiNose (OPTN) United States $0.283B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.278B 0.00
BioCryst Pharmaceuticals (BCRX) United States $0.270B 0.00
Molecular Templates (MTEM) United States $0.253B 0.00
Recro Pharma (REPH) United States $0.248B 0.00
La Jolla Pharmaceutical (LJPC) United States $0.228B 0.00
Xeris Pharmaceuticals (XERS) United States $0.212B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.208B 0.00
GlycoMimetics (GLYC) United States $0.198B 0.00
KalVista Pharmaceuticals (KALV) United States $0.196B 0.00
CV Sciences (CVSI) United States $0.196B 0.00
Nature's Sunshine Products (NATR) United States $0.178B 29.77
AcelRx Pharmaceuticals (ACRX) United States $0.174B 0.00
Foamix Pharmaceuticals (FOMX) Israel $0.171B 0.00
Taiwan Liposome (TLC) Taiwan $0.160B 0.00
Calithera Biosciences (CALA) United States $0.140B 0.00
Concert Pharmaceuticals (CNCE) United States $0.140B 0.00
Ocular Therapeutix (OCUL) United States $0.139B 0.00
Oasmia Pharmaceutical AB (OASMY) Sweden $0.135B 0.00
IMV INC (IMV) Canada $0.132B 0.00
Generex Biotechnology (GNBT) United States $0.131B 0.00
CannTrust Holdings (CTST) Canada $0.130B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $0.128B 0.00
Redhill Biopharma (RDHL) Israel $0.126B 0.00
MEI Pharma (MEIP) United States $0.118B 0.00
ALLERGY THERAPT (AGYTF) United Kingdom $0.108B 0.00
Jounce Therapeutics (JNCE) United States $0.108B 0.00
Cardiome Pharma (CORV) Canada $0.086B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.086B 32.94
MediWound (MDWD) Israel $0.081B 0.00
Aquestive Therapeutics (AQST) United States $0.081B 0.00
ASSERTIO THERAPEUTICS, INC (ASRT) United States $0.080B 0.00
Majesco Entertainment (PTE) United States $0.079B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.078B 0.00
Entasis Therapeutics Holdings (ETTX) United States $0.077B 0.00
Neos Therapeutics (NEOS) United States $0.071B 0.00
Lipocine (LPCN) United States $0.069B 0.00
Otonomy (OTIC) United States $0.069B 0.00
Champions Oncology (CSBR) United States $0.069B 0.00
Genocea Biosciences (GNCA) United States $0.069B 0.00
RENEURON GP (RNUGF) United Kingdom $0.065B 0.00
Novan (NOVN) United States $0.063B 0.00
Natural Alternatives (NAII) United States $0.062B 9.35
ElectroCore (ECOR) United States $0.061B 0.00
Iterum Therapeutics (ITRM) Ireland $0.060B 0.00
Infinity Pharmaceuticals (INFI) United States $0.060B 0.00
IntelGenx Technologies (IGXT) Canada $0.060B 0.00
Aclaris Therapeutics (ACRS) United States $0.059B 0.00
SCYNEXIS (SCYX) United States $0.058B 0.00
Opiant Pharmaceuticals (OPNT) United States $0.057B 0.00
Pharmaxis (PXSLY) Australia $0.055B 0.00
Nivalis Therapeutics (ALPN) United States $0.054B 0.00
Summit Therapeutics (SMMT) United Kingdom $0.053B 1.83
Melinta Therapeutics (MLNT) United States $0.052B 0.00
Capnia (SLNO) United States $0.051B 0.00
Forward Pharma (FWP) Denmark $0.047B 0.00
CTI BioPharma (CTIC) United States $0.045B 0.00
Dipexium Pharmaceuticals (PLXP) United States $0.042B 0.00
Mannatechorporated (MTEX) United States $0.040B 0.00
Bellicum Pharmaceuticals (BLCM) United States $0.040B 0.00
Mast Therapeutics (SVRA) United States $0.037B 0.00
Adamis Pharmaceuticals (ADMP) United States $0.033B 0.00
Jaguar Animal Health (JAGX) United States $0.033B 0.00
China SXT Pharmaceuticals (SXTC) China $0.031B 0.00
PharmAthene (ALT) United States $0.030B 0.00
Opexa Therapeutics (ACER) United States $0.030B 0.00
Biomerica (BMRA) United States $0.029B 0.00
Bio-Path Holdings (BPTH) United States $0.028B 0.00
ProPhase Labs (PRPH) United States $0.022B 0.00
Heat Biologics (HTBX) United States $0.014B 0.00
Kitov Pharmaceuticals Holdings (KTOV) Israel $0.014B 0.00
Cyanotech (CYAN) United States $0.014B 0.00
Vical (BBI) United States $0.014B 0.00
Regulus Therapeutics (RGLS) United States $0.013B 0.00
Achieve Life Sciences (ACHV) United States $0.013B 0.00
Shineco (TYHT) China $0.012B 17.67
HANCOCK JAFFE (HJLI) United States $0.012B 0.00
Eyegate Pharmaceuticals (EYEG) United States $0.010B 0.00
Tetraphase Pharmaceuticals (TTPH) United States $0.010B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.007B 0.00
VAXART, INC (VXRT) United States $0.006B 0.00
RXi Pharmaceuticals (PHIO) United States $0.006B 0.00
Onconova Therapeutics (ONTX) United States $0.005B 0.00
Midatech Pharma (MTP) United Kingdom $0.004B 0.00
Xenetic Biosciences (XBIO) United States $0.004B 0.00
Flex Pharma (SLRX) United States $0.004B 0.00
Cytori Therapeutics Inc (PSTV) United States $0.001B 0.00
Advanced Accelerator Applications S.A (AAAP) France $0.000B 0.00
Patheon (PTHN) Netherlands $0.000B 0.00